Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

1.0K
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
1.0K
Depression: Overview01:18

Depression: Overview

1.2K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.2K
Long-term Depression01:05

Long-term Depression

33.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.6K
Long-term Depression01:03

Long-term Depression

3.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.5K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

834
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
834
Diagnostic and Statistical Manual of Mental Disorders (DSM)01:27

Diagnostic and Statistical Manual of Mental Disorders (DSM)

1.5K
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Putting a Glucagon-Like Peptide-1 Receptor Agonist Trial for Type 2 Diabetes in Context.

JAMA network open·2026
Same author

UPPS-P Impulsivity, Momentary Affect, and Gambling: An Experience Sampling Method Study.

Journal of psychopathology and behavioral assessment·2026
Same author

Neurocognitive Disorders: Systematic Review of Approved (2008-2024) and Pipeline Phase III Medications.

Innovations in clinical neuroscience·2026
Same author

Sociodemographic Disparities in Emergency Department Wait Times at an Urban Academic Medical Center.

The Journal of emergency medicine·2026
Same author

Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts.

Diabetes technology & therapeutics·2025
Same author

Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Diabetes care·2025
Same journal

Frailty and its association with mental health and quality of life in multiple sclerosis: A cross-sectional study.

Therapeutic advances in chronic disease·2026
Same journal

Factors associated with disease knowledge and medication adherence among rheumatoid arthritis patients attending a private rheumatology clinic: A cross-sectional study.

Therapeutic advances in chronic disease·2026
Same journal

The evolving roles of fetuin-A in type 2 diabetes mellitus and its potential clinical implications: a review.

Therapeutic advances in chronic disease·2025
Same journal

Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication.

Therapeutic advances in chronic disease·2025
Same journal

Staging and markers in Parkinson's disease and Lewy body disorders: narrative review.

Therapeutic advances in chronic disease·2025
Same journal

A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe.

Therapeutic advances in chronic disease·2025
See all related articles

Related Experiment Video

Updated: Mar 18, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.6K

Patient-reported functioning in major depressive disorder.

Waguih William IsHak1, David M James2, James Mirocha2

  • 1Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center, 8730 Alden Drive, Thalians E-132, Los Angeles, CA 90048, USA.

Therapeutic Advances in Chronic Disease
|June 28, 2016
PubMed
Summary
This summary is machine-generated.

Major depressive disorder (MDD) treatment improves functioning, but most patients still experience deficits. Functioning declines post-treatment, especially for non-remitted patients, highlighting the need for personalized interventions.

Keywords:
Sequenced Treatment Alternatives to Relieve Depression trialfunctional outcomesfunctioningmajor depressive disorder

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.3K

Related Experiment Videos

Last Updated: Mar 18, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.6K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.3K

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Neuroscience

Background:

  • Major depressive disorder (MDD) significantly impairs patient functioning beyond symptom resolution.
  • Assessing functional outcomes is crucial for evaluating comprehensive treatment effectiveness.

Purpose of the Study:

  • To examine the impact of MDD and its treatment on patient functioning.
  • To evaluate functional recovery rates at different treatment stages and post-treatment follow-up.

Main Methods:

  • Analysis of 2280 adult outpatients with MDD from the STAR*D trial.
  • Functioning assessed using the Work and Social Adjustment Scale (WSAS) at entry, exit, and 12-month follow-up.

Main Results:

  • Only 7% of patients reported normal functioning pre-treatment.
  • Treatment increased functioning, but over 60% remained impaired at exit.
  • Functioning declined at 12-month follow-up, particularly in non-remitted patients.

Conclusions:

  • Functional outcomes are critical in MDD treatment.
  • Current treatments inadequately restore functioning for many patients.
  • Personalized interventions are needed to improve long-term functioning in MDD.